Lexeo Therapeutics (LXEO) Stock Price, News & Analysis

Company Overview

Lexeo Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing gene therapies for genetic and acquired diseases. The company uses adeno-associated virus (AAV) delivery technology to introduce genetic material intended to address underlying disease mechanisms, with programs spanning central nervous system and cardiovascular conditions.

Lexeo’s development portfolio includes investigational therapies for APOE4-associated Alzheimer’s disease, Friedreich’s ataxia, and inherited cardiac disorders such as LMNA-related dilated cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy. Its candidates are in clinical development, and the company’s research and development activities are primarily focused on advancing these therapies through clinical testing and regulatory evaluation.

Founded in 2017 and headquartered in New York, Lexeo serves patients through a development program centered largely on the United States. The company is led by Chief Executive Officer R. Nolan Townsend and became a publicly traded company on the Nasdaq under the ticker symbol LXEO in 2023.

Key Stats

• Today's Range: $3.14 to $3.29
• 50-Day Range: $3.14 to $5.37
• 52-Week Range: $3.14 to $10.99
• Volume: 1.26 million shs
• Average Volume: 978,737 shs
• Market Capitalization: $257.64 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $18.13
• Consensus Rating: Buy

Lexeo Therapeutics Stock Analysis - MarketRank™

Lexeo Therapeutics scored higher than 50% of companies evaluated by MarketBeat, and ranked 550th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Buy

Consensus Rating

Lexeo Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 6 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Lexeo Therapeutics has a consensus price target of $18.13, representing about 477.2% upside from its current price of $3.14.

Amount of Analyst Coverage

Lexeo Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Lexeo Therapeutics are expected to decrease in the coming year, from ($1.18) to ($1.44) per share.

Price to Book Value per Share Ratio

Lexeo Therapeutics has a P/B Ratio of 0.93. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

25.66% of the float of Lexeo Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Lexeo Therapeutics has a short interest ratio ("days to cover") of 33.44, which indicates bearish sentiment.

Change versus previous month

Short interest in Lexeo Therapeutics has recently increased by 0.70%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lexeo Therapeutics does not currently pay a dividend.

Dividend Growth

Lexeo Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.30

News Sentiment

Lexeo Therapeutics has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 13 news articles for Lexeo Therapeutics this week, compared to 3 articles on an average week.

MarketBeat Follows

Only 1 people have added Lexeo Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Lexeo Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $299,817.00 in company stock.

Percentage Held by Insiders

2.00% of the stock of Lexeo Therapeutics is held by insiders.

Percentage Held by Institutions

60.67% of the stock of Lexeo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 9/28/2026
• Stifel 2026 Virtual Cardiometabolic Forum: 9/30/2026
• Next Earnings (Estimated): 12/14/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:LXEO
• Previous Symbol: NASDAQ:LXEO
• CIK: 1907108
• Web: www.lexeotx.com
• Phone: 212-547-9879
• Fax: N/A
• Employees: 59
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Lexeo Therapeutics: $18.13
• High Price Target: $30.00
• Low Price Target: $9.00
• Potential Upside/Downside: +477.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.15)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$99.96 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -41.85%
• Return on Assets: -38.03%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 13.89
• Quick Ratio: 13.89

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.38 per share
• Price / Book: 0.93

Miscellaneous

• Outstanding Shares: 82,050,000
• Free Float: 80,405,000
• Market Cap: $257.64 million
• Optionable: Not Optionable
• Beta: 1.50